Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 40HER2-positive Breast Cancer 6Neoplasm Metastasis 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Invasive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early Breast Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1Carcinoma, Ductal, Breast 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced HER2+Breast Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 10Radiotherapy 6Epirubicin 6Paclitaxel 5Docetaxel 5Trastuzumab 4Fluorouracil 4Doxorubicin 4Tamoxifen 3Neoadjuvant Therapy 3pertuzumab 2Surgical Procedures, Operative 2Filgrastim 2ferric carboxymaltose 1Thiotepa 1Taxes 1Razoxane 1Radiation 1Prochlorperazine 1Peripheral Blood Stem Cell Transplantation 1Palonosetron 1Microarray Analysis 1Methotrexate 1Injections, Subcutaneous 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Dexrazoxane 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Inflammatory Breast Neoplasms × pertuzumab × Clear all
NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡